Poxel S.A. (PXXLF)
| Previous close | 2.1000 |
| Open | 2.1000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.1000 - 2.1000 |
| 52-week range | 2.1000 - 9.2600 |
| Volume | |
| Avg. volume | 5 |
| Market cap | 52.68M |
| Beta (5Y monthly) | 1.62 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Poxel Announces Results from June 21, 2022 Ordinary Annual and Extraordinary General Meeting
LYON, France, June 22, 2022--POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces that it held its ordinary annual and extraordinary general meeting of shareholders on June 21, 2022. The meeting was held at Collège Hôtel, 5 Place Saint-Paul, 69005 LYON, and was chaired by Pierre
- Business Wire
Poxel Announces New Solid Form Patent for PXL065 that Provides Additional Protection through 2041
LYON, France, June 09, 2022--POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announced today that the U.S. Patent and Trademark Office (PTO) has issued to Poxel US Patent No. 11319313 which represents a new patent for PXL065, a novel, proprietary deuterium-stabilized R-stereoisomer of piogl
- Business Wire
Poxel Announces its Participation in Upcoming Investor and Scientific Conferences
LYON, France, May 31, 2022--POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces that the Poxel team will participate in several upcoming investor and scientific conferences in June 2022.
